Akeso, Inc. Reports Mixed Mid-Year Financial Results

Akeso, Inc. (HK:9926) has released an update.

Akeso, Inc., a biopharmaceutical firm specializing in innovative antibody drugs, has reported a decrease in revenue to RMB1,024.7 million and a loss of RMB249.3 million for the first half of 2024. Despite this, the company saw a 23.96% increase in net product sales, boosted by the growth in sales of its core bi-specific antibody drugs. The firm also expanded its licensing territory for the drug ivonescimab, adding to its revenue during the period.

For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.